Blueprint Medicines Makes Chris Varma Permanent CEO; Names Daniel Lynch Executive Chairman
Posted on: November 13, 2012 by Connie LoizosNo Comments »
Blueprint Medicines, a Cambridge, Mass.-based company that’s developing cancer therapies, has made Chris Varma, its founding president and an entrepreneur-in-residence at Third Rock Ventures, its permanent president and CEO. The company has also named Daniel Lynch as executive chairman of its board. Lynch spent nearly five years at ImClone Systems, including as CEO and CFO.




